GuangYuYuan Chinese Herbal Medicine (SHSE:600771) Investors Are up 5.0% in the Past Week, but Earnings Have Declined Over the Last Five Years
GuangYuYuan Chinese Herbal Medicine (SHSE:600771) Investors Are up 5.0% in the Past Week, but Earnings Have Declined Over the Last Five Years
When we invest, we're generally looking for stocks that outperform the market average. And while active stock picking involves risks (and requires diversification) it can also provide excess returns. For example, long term GuangYuYuan Chinese Herbal Medicine Co., Ltd. (SHSE:600771) shareholders have enjoyed a 45% share price rise over the last half decade, well in excess of the market return of around 26% (not including dividends).
After a strong gain in the past week, it's worth seeing if longer term returns have been driven by improving fundamentals.
We don't think that GuangYuYuan Chinese Herbal Medicine's modest trailing twelve month profit has the market's full attention at the moment. We think revenue is probably a better guide. Generally speaking, we'd consider a stock like this alongside loss-making companies, simply because the quantum of the profit is so low. For shareholders to have confidence a company will grow profits significantly, it must grow revenue.
In the last 5 years GuangYuYuan Chinese Herbal Medicine saw its revenue grow at 1.6% per year. That's not a very high growth rate considering the bottom line. The modest growth is probably broadly reflected in the share price, which is up 8%, per year over 5 years. We'd be looking for the underlying business to grow revenue a bit faster.
The company's revenue and earnings (over time) are depicted in the image below (click to see the exact numbers).
Take a more thorough look at GuangYuYuan Chinese Herbal Medicine's financial health with this free report on its balance sheet.
A Different Perspective
While the broader market gained around 13% in the last year, GuangYuYuan Chinese Herbal Medicine shareholders lost 29%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. On the bright side, long term shareholders have made money, with a gain of 8% per year over half a decade. If the fundamental data continues to indicate long term sustainable growth, the current sell-off could be an opportunity worth considering. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. For example, we've discovered 1 warning sign for GuangYuYuan Chinese Herbal Medicine that you should be aware of before investing here.
If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: many of them are unnoticed AND have attractive valuation).
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.